|1.||Su, Ming-Jai: 2 articles (07/2008 - 03/2008)|
|2.||Lee, An-Sheng: 2 articles (07/2008 - 03/2008)|
|3.||Tsukamoto, Hidetoshi: 2 articles (01/2006 - 09/2003)|
|4.||Mishima, Hiromu K: 2 articles (01/2006 - 09/2003)|
|5.||Oku, Hidehiro: 2 articles (02/2005 - 01/2005)|
|6.||Hara, Hideaki: 2 articles (01/2005 - 09/2004)|
|7.||Ichikawa, Masaki: 2 articles (01/2005 - 09/2004)|
|8.||Kawamori, Ryuzo: 1 article (06/2014)|
|9.||Yasunari, Eisuke: 1 article (06/2014)|
|10.||Azuma, Kosuke: 1 article (06/2014)|
|1.||Hypertension (High Blood Pressure)
10/01/1993 - "In conclusions, in mild/moderate arterial hypertension, bunazosin in monotherapy at the dosage of 3-6 mg/day, is an effective and safe treatment."
10/01/1993 - "The aim of this study was to identify the minimum effective dose of bunazosin in the treatment of mild-moderate arterial hypertension. "
10/01/1993 - "[Dose-response study of bunazosin in the treatment of light-to-moderate arterial hypertension]."
05/01/1990 - "The results of this short-term study suggest that bunazosin may be a drug that will increase RBF and GFR and decrease TRR with a concomitant hypotensive action in patients with mild-to-moderate essential hypertension. "
11/01/1995 - "Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension. "
|2.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
05/01/1992 - "These findings showed that bunazosin hydrochloride is beneficial for the treatment of prostatic hyperplasia, and could be safety administered for a prolonged period of time up to 12 weeks."
10/01/1990 - "[A double-blind trial on the effect of bunazosin hydrochloride for the symptoms of benign prostatic hypertrophy]."
05/01/1992 - "[The evaluation of the effects of bunazosin hydrochloride in the treatment of prostatic hyperplasia]."
09/01/1991 - "The binding properties of a new radioligand, [3H]bunazosin, were studied in membranes of human prostates with benign prostatic hypertrophy (BPH). "
06/01/1991 - "Since this radioligand binding assay using [3H]bunazosin demonstrated the presence of alpha 1-adrenoceptors in bovine prostates, this method is useful for the assessment of alpha 1-blockers of new chemicals synthesized for the treatment of the benign prostatic hyperplasia."
|3.||Neurogenic Urinary Bladder (Bladder, Neurogenic)
10/01/1990 - "The therapeutic utility of bunazosin hydrochloride was evaluated by a multi-center (67 hospitals) double-blind controlled study in patients who complained of voiding disturbances due to neurogenic bladder. "
09/01/1987 - "[Clinical study of bunazosin hydrochloride, an alpha 1-adrenergic blocker, in benign prostatic obstruction and neurogenic bladder dysfunction]."
02/01/1992 - "Bunazosin hydrochloride (Ea-0643), a selective alpha 1-blocker, was administered to 14 patients with neurogenic bladder over prolonged periods of time in order to determine its efficacy and safety. "
02/01/1992 - "[Usefulness and safety of bunazosin hydrochloride in neurogenic bladder after prolonged administration]."
10/01/1990 - "[Clinical evaluation of bunazosin hydrochloride for the treatment of voiding disturbances due to neurogenic bladder--a double-blind study]."
02/01/2005 - "Amelioration of endothelin-1-induced optic nerve head ischemia by topical bunazosin."
12/01/1998 - "Bunazosin alone reversed the ischemia-related shortening of ERPs at both the endocardial and epicardial sites, with a greater effect seen epicardially (P < .05). "
12/01/1997 - "Treatment with bunazosin ameliorated this ischemia-related shortening of refractory periods at both the endo- and epicardial sites, with a greater effect seen epicardially (p < 0.05), resulting in values similar to those in the nonischemic tissue. "
08/01/1990 - "It is concluded that bunazosin may reduce the influence of ischemia on the myocardium."
08/01/1990 - "Bunazosin also prevented the changes in carbohydrate metabolism caused by ischemia. "
|5.||Cardiomegaly (Heart Hypertrophy)
09/01/1993 - "In this study, bunazosin, a selective alpha 1-blocker, (15 mg/kg/day in food) was given to male spontaneously hypertensive rats (SHR) from 15 to 35 weeks of age to evaluate its effects on cardiac hypertrophy, hemodynamics, and neurohumoral factors. "
09/01/1996 - "To assess the protective effect of an alpha 1-blocker on the development of cardiac hypertrophy, the selective alpha 1-receptor antagonist bunazosin (2 mg/kg/d, by oral gavage and in drinking water) was given to male Dahl salt-sensitive rats fed a 4% NaCl diet for 7 weeks. "
09/01/1996 - "Prevention of cardiac hypertrophy by a sub-antihypertensive dose of the alpha 1-adrenergic antagonist bunazosin in Dahl salt-sensitive rats."
07/01/1991 - "These results indicate that long term treatment with bunazosin hydrochloride reduces blood pressure and leads to the regression of cardiac hypertrophy in SHR. "
09/01/1996 - "The results indicate that a sub-antihypertensive dose of bunazosin can inhibit the development of cardiac hypertrophy without suppression of the pressure load, suggesting an important role of alpha 1-adrenergic receptors in the pathogenesis of cardiac hypertrophy following the development of hypertension."
|3.||Adrenergic Antagonists (Antiadrenergic Agents)
|6.||Adenosine Triphosphate (ATP)
|7.||Adrenergic Receptors (Adrenergic Receptor)